Horizon Kinetics Asset Management LLC Cuts Stock Position in Danaher Co. (NYSE:DHR)

Horizon Kinetics Asset Management LLC lowered its holdings in Danaher Co. (NYSE:DHR) by 1.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,871 shares of the conglomerate’s stock after selling 137 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Danaher were worth $2,466,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in DHR. Benjamin Edwards Inc. increased its position in shares of Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 38 shares during the period. Wedge Capital Management L L P NC increased its holdings in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. raised its position in Danaher by 3.4% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after purchasing an additional 40 shares in the last quarter. Trust Co of Kansas grew its position in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock worth $255,000 after buying an additional 40 shares in the last quarter. Finally, Abacus Planning Group Inc. increased its stake in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after buying an additional 40 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

Danaher stock opened at $237.77 on Monday. The business has a 50 day simple moving average of $258.15 and a 200-day simple moving average of $260.03. Danaher Co. has a 12 month low of $215.68 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The stock has a market capitalization of $171.74 billion, a PE ratio of 45.01, a price-to-earnings-growth ratio of 4.34 and a beta of 0.85.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the business earned $2.02 EPS. The business’s revenue was up 3.1% on a year-over-year basis. Equities analysts predict that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. KeyCorp increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Monday, November 18th. UBS Group cut their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Raymond James dropped their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, Evercore ISI boosted their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.